In a study published by Zang et al in JAMA Oncology, investigators sought to assess the association of tumor mutational burden status with outcomes in metastatic castration-resistant prostate cancer and response to immune checkpoint inhibition.
Question 1 of 5
What was the overall response rate to treatment with immunotherapy in the tumor mutational burden (TMB)-high group compared to the TMB-low/-medium group in this study?
